Quviviq (Daridorexant) for Insomnia: What to Know

Sleep medicines fall into two groups. Some — zolpidem, eszopiclone — are approved by the FDA for insomnia. Others, like trazodone, mirtazapine and quetiapine, are approved for something else and get used for sleep because they cause drowsiness. Quviviq is in the first group, and it works differently from most of it: rather than increasing the brain chemicals that slow activity down, it blocks one that keeps you awake.

What the label says

Quviviq is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.1

That matters, because not every sleep medicine addresses the same problem. The AASM's 2017 guideline suggests some drugs only for falling asleep — ramelteon — and others only for staying asleep, such as low-dose doxepin.4

How it works

Daridorexant is a dual orexin receptor antagonist. Orexin is a signaling chemical that helps keep you awake; daridorexant blocks the receptors it acts on, which dampens the drive to stay awake.1

Most other sleep medicines work from the other direction. Zolpidem and the benzodiazepines boost GABA, which slows brain activity down. Quviviq instead takes away a wakefulness signal. It can still leave you drowsy, and the label advises caution with driving and other activities needing full alertness.1

Suvorexant, an older drug in the same class, is one of the agents the AASM suggests for sleep-maintenance insomnia. Daridorexant was approved in 2022, after that guideline was published, so the guideline does not assess it either way.4

Dose and timing

The recommended dosage is 25 mg to 50 mg once per night, taken within 30 minutes of going to bed, with at least seven hours remaining before you plan to wake up.1

The seven-hour window is not a suggestion. Taking it without a full night ahead of you raises the chance of being drowsy or impaired the next day, including behind the wheel.

Quviviq is a Schedule IV controlled substance1 — the same schedule as zolpidem and the benzodiazepines used for sleep, reflecting a recognized but relatively low potential for abuse and dependence.

Side effects

In the three-month placebo-controlled study in the label, the most common adverse reactions were:1

Those gaps are small. The label still notes that somnolence and fatigue become more likely with age, and that drowsiness raises the risk of falls in older adults.1

Two warnings are worth reading twice. Driving: in a driving study, some people taking the 50 mg dose showed next-morning impairment, and the label advises caution the day after a dose.1 Alcohol: do not drink with it — the combination amplifies the effects on reaction time and coordination.1

What the trials showed

In two phase 3 trials, daridorexant 25 mg and 50 mg improved sleep onset, sleep maintenance and self-reported total sleep time against placebo at one and three months; only the 50 mg dose improved daytime sleepiness scores.2 A separate extension study found up to twelve months of treatment generally well tolerated, with no withdrawal symptoms or rebound insomnia on stopping.3

Where it sits in treatment

Being approved for insomnia puts Quviviq on firmer ground than many drugs people take for sleep. It does not move it to the front of the queue.

US guidelines recommend CBT-I as first-line treatment for chronic insomnia in adults, with medication a shared decision if CBT-I alone has not been enough.78 The 2025 VA/DoD guideline takes the same position, suggesting CBT-I over medication first, and listing daridorexant among the agents it suggests when medication is offered.5 The European guideline allows orexin receptor antagonists for up to three months, and longer in some cases.6

The distinction that matters: a medicine works for as long as you take it. CBT-I works on the habits and thoughts keeping insomnia going, so its benefit tends to outlast the treatment.